| DVLT |
Datavault AI Inc. |
92%
|
Reciprocal relationship from DVLT graph: department, 85 employees in our general and administrative department. None of our employees are represented by a labor union with respect to his or her emplo… |
| ORMP |
Oramed Pharmaceuticals Inc. |
92%
|
Reciprocal relationship from ORMP graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from ORMP graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from ORMP g… |
| PHOENIX-ASIA-HOLDINGS-LIMITED |
PHOENIX-ASIA-HOLDINGS-LIMITED |
90%
|
Phoenix Asia agreed to purchase, 100% of the issued and outstanding shares of common stock of ACEA Pharma |
| AMERISOURCEBERGEN-CORPORATION |
AMERISOURCEBERGEN-CORPORATION |
85%
|
alth 110, LLC (“Cardinal Health 110”) and AmerisourceBergen Corporation (“AmerisourceBergen”). Distributors have agreements in place that provide us with access to large retail chains, including CVS,… |
| MCK |
McKesson Corporation |
85%
|
Reciprocal relationship from MCK graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from MCK graph: Reciprocal relationship from SCLX graph: 5, LLC (“Cardinal Health 105”), ships… |
| MCK |
McKesson Corporation |
85%
|
5, LLC (“Cardinal Health 105”), ships them to temperature-controlled customer distribution centers, which are generally able to deliver finished product to retail pharmacies on the same day, or withi… |
| A |
Agilent Technologies, Inc. |
72%
|
Reciprocal relationship from A graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from A graph: Reciprocal relationship from SCLX graph: ury strategy would be delayed, which coul… |
| A |
Agilent Technologies, Inc. |
72%
|
ury strategy would be delayed, which could cause a material adverse effect on our business, prospects, and market price of our listed securities. If we are not able to enter into a custodial agreemen… |
| AARD |
Aardvark Therapeutics, Inc. |
72%
|
Reciprocal relationship from AARD graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from AARD graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from AARD g… |
| AARD |
Aardvark Therapeutics, Inc. |
72%
|
ement with EAR SPV LLC, a Delaware corporation (“EAR SPV”) and Vivasor Holding Company (“VHC”), a privately held biotechnology company, pursuant to which, among other things, EAR SPV agreed to sell, … |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from SCLX graph: to promote GLOPERBA® for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree of overlap b… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
to promote GLOPERBA® for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree of overlap between the current HCPs that we target and HCPs who prescribe colchicine for gout… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from SCLX graph: to promote GLOPERBA® for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree of overlap… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
to promote GLOPERBA® for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree of overlap between the current HCPs that we target and HCPs who prescribe colchicine for gout… |
| COLL |
Collegium Pharmaceutical, Inc. |
72%
|
Reciprocal relationship from COLL graph: Reciprocal relationship from SCLX graph: alth 110, LLC (“Cardinal Health 110”) and AmerisourceBergen Corporation (“AmerisourceBergen”). Distributors have agre… |
| COLL |
Collegium Pharmaceutical, Inc. |
72%
|
alth 110, LLC (“Cardinal Health 110”) and AmerisourceBergen Corporation (“AmerisourceBergen”). Distributors have agreements in place that provide us with access to large retail chains, including CVS,… |
| SCLXW |
SCLXW |
72%
|
Reciprocal relationship from SCLXW graph: ts obligation assumed by Sorrento $ $ $ See accompanying notes to audited consolidated financial statements F- 7 SCILEX HOLDING COMPANY NOTES TO CONSOLIDATE … |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from SCLX graph: arket uptake. Prescription Lidocaine Patch Market Overview Prescription lidocaine patches are approved by the FDA as… |
| SNYNF |
Sanofi |
72%
|
arket uptake. Prescription Lidocaine Patch Market Overview Prescription lidocaine patches are approved by the FDA as a local anesthetic and are generally used as a first-line treatment for the relief… |
| DECISION-RESOURCES-GROUP |
DECISION-RESOURCES-GROUP |
62%
|
arket uptake. Prescription Lidocaine Patch Market Overview Prescription lidocaine patches are approved by the FDA as a local anesthetic and are generally used as a first-line treatment for the relief… |
| PAR |
PAR Technology Corporation |
62%
|
Reciprocal relationship from PAR graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from PAR graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from PAR grap… |
